Abbott Showcases Comprehensive Hepatitis Diagnostic Portfolio at CIIE to Advance Elimination Goals
Abbott
Diagnostic and pharmaceutical product manufacturers
On November 6, 2023, during the sixth China International Import Expo (CIIE), Abbott, a global leading healthcare company, held the thematic event "Path to Liver Healing: Insights and Perspectives." Leveraging the CIIE platform, Abbott’s four major diagnostic businesses jointly launched a full-line initiative aimed at collaboratively exploring comprehensive prevention and control strategies for viral hepatitis, advancing China's efforts in viral hepatitis prevention and control, supporting the goal of "fully implementing various measures for viral hepatitis prevention and treatment" in China, and contributing to the World Health Organization's vision of "eliminating viral hepatitis as a public health threat by 2030."
From left to right: Joanne Lu, Director of Public Affairs, Greater China, Abbott; Wei Wang, General Manager, China, Abbott Point-of-Care Diagnostics; Ying Chen, Vice President, Global Core Diagnostics, Abbott; Jianping Qiu, General Manager, Greater China, Abbott Rapid Diagnostics; Yi Dai, General Manager, China, Abbott Molecular Diagnostics; and Jun Ji, Human Resources Director, Greater China, Abbott, attended the launch ceremony of Abbott Diagnostics' full-line initiative.
The "2022 National Overview of Notifiable Infectious Disease Epidemics" released by the National Health Commission shows that viral hepatitis ranks first in the number of new cases among Class B infectious diseases in China.1It is estimated that there are approximately 86 million people infected with the hepatitis B virus in China.2, approximately 10 million people are infected with the hepatitis C virus.3Due to the hidden onset and inconspicuous symptoms of hepatitis B and C, approximately 60% of liver cancer cases are caused by the lack of timely detection and treatment of viral hepatitis B and C.4Most people with hepatitis B and C are unaware of their infection status, often seeking medical attention only when the disease has progressed to an advanced stage, thus delaying the optimal treatment period. Data shows that the diagnosis rates for hepatitis B and C in China are still unsatisfactory, both below 30%.5, there is an urgent need to further expand the population for viral hepatitis screening in order to detect patients with potential disease progression risks who require treatment as early as possible.
As a global leader in the diagnostics industry, Abbott has a comprehensive diagnostics business, including core diagnostics, rapid diagnostics, point-of-care diagnostics, and molecular diagnostics, which can maximize the testing needs of different application scenarios in disease management, providing timely and accurate information to assist in medical decision-making. For the screening and prevention of viral hepatitis, Abbott provides a full range of diagnostic solutions covering the entire disease management process, fully meeting the health management needs of different medical scenarios:
Accurate and Sensitive Laboratory Testing
Helping clinicians diagnose early and seize the optimal treatment time is the key to curbing the harm of viral hepatitis.Ying Chen, Global Vice President of Abbott's Core Diagnostics BusinessIntroduction: Since the launch of the world's first hepatitis B surface antigen test kit in 1972, Abbott Core Diagnostics has possessedComprehensive Hepatitis Immune Testing ProgramTo meet health screening needs, including screening for multiple pathogens such as hepatitis B virus (HBV) and hepatitis C virus (HCV), helping doctors make clinical decisions promptly, wisely, and confidently. In addition, Abbott has developed the ASAP liver cancer risk assessment model, a diagnostic model for hepatitis B-related liver cancer tailored to the Chinese population. This model is instructive in assessing the risk of liver cancer in hepatitis B patients and has proven highly effective in assisting doctors with early disease screening and diagnosis, enhancing clinical confidence, and reducing medical costs.
Ying Chen, Global Vice President of Abbott's Core Diagnostics Business
Abbott GLP Laboratory Automation System and Abbott Alinity ci Biochemical Immunoassay Platform
Applicable to diverse scenarios, easy to operate, fast speed, and high sensitivityRapid Detection Technology
Promotion in ChinaExpand Viral Hepatitis Screening CampaignDoubly beneficial.Jianping Qiu, General Manager of Abbott Rapid Diagnostics Business in Greater ChinaAbbott's rapid diagnostic hepatitis testing products can determine whether a person is infected with the hepatitis virus within a short period of time, fully meeting clinical testing needs in various application scenarios, such as those involving detection by medical systems at all levels.Abbott ABON HBsAg (Hepatitis B Virus Surface Antigen), ABON HBsAb (Hepatitis B Virus Surface Antibody), and ABON HCV ProductsHave been successfully applied in multiple regional viral hepatitis detection projects in China, post-vaccination testing for children, as well as regional epidemiological surveillance and integrated HCV diagnosis and treatment projects.
Jianping Qiu, General Manager of Abbott Rapid Diagnostics Business in Greater China
Abbott Rapid Diagnostics Portfolio
In the management of hepatitis, precise treatment, and prognosis, etc.
Cutting-edge molecular diagnostic technologies in the industry can quantitatively detect viral load in the body, determine infectivity, and thereby assist doctors in dynamically monitoring treatment responses and supporting medication therapy.Yi Dai, General Manager of Abbott's Molecular Diagnostics Business in ChinaIndicates,Abbott Alinity m* Fully Automated Real-Time Fluorescence Nucleic Acid Amplification Analysis SystemSuitable for the detection of various infectious diseases, including hepatitis B, hepatitis C, etc., capable of random sampling and emergency sampling during the testing process, and obtaining the first batch of test results within two hours, providing clinicians and patients with faster, more sensitive, and more accurate molecular test results.
Yi Dai, General Manager of Abbott's Molecular Diagnostics Business in China
Abbott Alinity m* Fully Automated Real-Time Fluorescence Nucleic Acid Amplification Analysis System
Liver Transplantation
As the ultimate treatment for end-stage liver disease patients, every step—from the procurement, preservation, and transportation of transplantable livers to the final transplantation surgery—must be highly coordinated and performed with utmost urgency.Point-of-care testing enables on-site sampling, rapid analysis, and minimizes the turnaround time for testing within a short period., helping surgeons quickly diagnose and more precisely control every step of the liver transplant process.Wang Wei, General Manager of Abbott's Point-of-Care Diagnostics Business in ChinaIntroduction, Abbotti-STAT Handheld Blood AnalyzerWith its versatile functions, flexible portability, instant availability, and precise quantification, it can assist Organ Procurement Organizations (OPO) teams in traveling to various locations, quickly assessing donor conditions on-site, and aiding in intraoperative monitoring during transplantation to ensure surgical safety and save more lives. In addition, i-STAT is widely used in emergency rooms, ICUs, operating rooms, disaster relief operations, as well as grassroots medical institutions and remote areas, providing test results for 23 items in blood within 2-10 minutes, offering critical support for treatment during urgent moments.
Wang Wei, General Manager of Abbott's Point-of-Care Diagnostics Business in China
Abbott i-STAT Alinity Portable Blood Analyzer
As a leader in the field of blood screening and infectious disease testing, Abbott began operations in 1994.Global Virus Surveillance Program, monitoring HIV virus, hepatitis virus mutations, etc., to ensure that the company's diagnostic testing solutions remain up-to-date. In 2021, Abbott announced the establishment ofAbbott Pandemic Defense Coalition (APDC)This is the world's first scientific and public health cooperation network dedicated to the early detection and rapid response to future pandemic threats. The coalition aims to assist the global scientific community and health organizations in identifying new viruses, taking swift action when viral threats are detected, and helping to prevent future pandemics. It also seeks to strengthen global collaboration and R&D innovation, rapidly developing and deploying diagnostic methods and tools to address emerging infectious disease threats in a timely manner. This initiative further expands Abbott's ongoing virus surveillance and discovery efforts over the past three decades.
In addition, Abbott has also developed a number ofDisease Risk Assessment Model，Covering multiple major disease screenings such as cancer, cardiovascular diseases, infectious diseases and other fields, providing the public with forward-looking health risk assessments and comprehensive medical guidance.
Abbott always pays attention to the development needs of China's healthcare industry and is committed to working with all parties to continuously deepen its presence in the Chinese market. This year, Abbott's integrated customer experience center in China —Abbott Innovation Center Upgraded, by showcasing comprehensive diagnostic solutions for various medical application scenarios, providing professional training and remote technical support, Abbott helps hospitals and laboratories in China enhance the quality and efficiency of diagnostics. Through the establishment ofAbbott Diagnostics AcademyAbbott has gathered top experts in the field of laboratory medicine in China, established a professional exchange platform, and supported the training and growth of laboratory professionals in China. As a global leader in the diagnostics industry, Abbott will continue to innovate and provide comprehensive disease diagnostic solutions to help people safeguard their health and contribute to the realization of the "Healthy China 2030" vision.